This inventor holds 7 USPTO granted patents and 5 published patent applications and 4 EPO patents. Top assignees: Eli Lilly and Company, Boehringer Ingelheim International Gmbh, Boehringer Ingelheim Pharma Gmbh & Co Kg. Active years: 2011-2015.
Location History:
- Notts, GB (2011)
- Basingstoke, GB (2011 - 2013)
- Abingdon, GB (2012 - 2015)
Company Filing History:
5 out of 4,509 
1 out of 1,561 
1 out of 194 
Years Active: 2011-2015
Title: The Innovations of Michael Philip Mazanetz
Introduction
Michael Philip Mazanetz is a notable inventor based in Abingdon, GB, with a remarkable portfolio of seven patents to his name. His work primarily focuses on advancements in the pharmaceutical field, particularly in the development of novel medicaments.
Latest Patents
Among his latest innovations are patents related to substituted naphthyridines, specifically their use as medicaments. These inventions encompass new substituted naphthyridines of formula 1, alongside pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates, or solvates thereof, where 'n' may either be 0 or 1. This substantial contribution to medicinal chemistry highlights his dedication to enhancing therapeutic solutions.
Career Highlights
Over the years, Michael has significantly impacted the pharmaceutical industry through his tenure at esteemed companies such as Eli Lilly and Company and Boehringer Ingelheim Pharma GmbH & Co. KG. His innovative spirit and commitment to research have not only advanced drug development but also reinforced the importance of intellectual property in fostering innovation.
Collaborations
Throughout his career, Michael has collaborated with several accomplished professionals, including Andrew Caerwyn Williams and Karin Briner. These partnerships have facilitated the exchange of ideas and further propelled his inventive efforts in creating valuable medicinal products.
Conclusion
Michael Philip Mazanetz exemplifies the role of an inventive mind in the pharmaceutical sector, with his contributions leading to significant advancements in medicament development. His continued dedication to innovation serves as an inspiration to both current and future inventors.